Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2025-12-27 @ 6:53 AM
Study NCT ID:
NCT00524368
Status:
COMPLETED
Last Update Posted:
2013-02-15
First Post:
2007-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CR013783
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None